Harrow to Present at Two Investor Conferences in November

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences:

BTIG 3^rd Annual Ophthalmology Day
Format: Fireside Chat (Virtual)
Date/Time: Monday, November 27, 2023, at 1:30 p.m. ET

Piper Sandler 35^th Annual Healthcare Conference (The Lotte New York Palace, New York, NY)
Format: Fireside Chat (In-Person)
Date/Time: Thursday, November 30, 2023, at 8:00 a.m. ET

Harrow management will be available for one-on-one meetings during both conferences. Investors interested in meeting with management should contact their BTIG or Piper Sandler representative to request a meeting.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit harrow.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120551397/en/

The Harrow Health Stock at the time of publication of the news with a raise of 0,00 % to 8,96USD on Nasdaq stock exchange (18. November 2023, 02:00 Uhr).